Status:
UNKNOWN
Multicenter Clinical Research for Early Diagnosis of Lung Cancer Using Blood Plasma Derived Exosome
Lead Sponsor:
Korea University Guro Hospital
Conditions:
Lung Cancer
Eligibility:
All Genders
40+ years
Brief Summary
Lung cancer is a leading cause of cancer death worldwide. Early diagnosis is linked to a better prognosis. Further, surgical resection at the early stages of non-small cell lung cancer (NSCLC) results...
Eligibility Criteria
Inclusion
- Patients with primary adenocarcinoma of lung with permanent pathology of N0 or N1
- Patients with T1mi, Tsi, T1a, T1b, T1c, T2a, and T2b stage
- An adult of Korean nationality
- Patients without prior chemo/radiation treatment prior to lung cancer surgery
- Patients who have not been diagnosed with other cancers prior to lung cancer surgery
Exclusion
- Patients who do not meet the inclusion criteria
Key Trial Info
Start Date :
April 9 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 29 2023
Estimated Enrollment :
470 Patients enrolled
Trial Details
Trial ID
NCT04529915
Start Date
April 9 2020
End Date
December 29 2023
Last Update
December 30 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Korea University Guro Hospital
Seoul, Guro-gu, South Korea, 08308